Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AHCC in Ovarian Cancer Patients on Adjuvant Chemotherapy
NCT05763199Phase 2Active, not recruiting
- Sponsor
- University of California, Davis
- Start
- Aug 2023
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ovarian epithelial carcinoma, fallopian tube carcinoma (PFTC) and primary peritoneal carcinoma (PPC) (2 arms), sponsored by University of California, Davis. Primary endpoints: Proportion of participants consent and randomized, Time required to randomize 20 participants and 1 more. Started Aug 2023; status: active, not recruiting.
02
Conditions
ovarian epithelial carcinomafallopian tube carcinoma (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT05763199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05763199.